相关实验视频

Updated: Mar 10, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

氨酸通过IL-6/JAK2/STAT3通路抑制PD-L1,以抑制骨髓瘤中的免疫逃避

Rui Gong¹, Xi-Min Jin¹, Xu Cui¹

¹First Clinical College, Shandong University of Traditional Chinese Medicine, Jinan, China.

Frontiers in immunology

|March 9, 2026

概括

中发现的一种化合物素通过通过IL-6/JAK2/STAT3通路降低PD-L1表达的调节来抑制骨肉瘤的进展. 这增强了抗瘤免疫力,减少了免疫逃避,显示了免疫治疗的潜力.

科学领域:

免疫学和癌症研究
分子生物学和信号通路
药理学和自然化合物

背景情况:

编程死亡配体1 (PD-L1) 是一种关键的免疫检查点蛋白,可以抑制T细胞的反应.
骨髓瘤表现出免疫逃避,阻碍有效的抗瘤免疫力.
IL-6/JAK2/STAT3通路与各种癌症有关,包括骨肉瘤.

研究的目的:

为了研究素是否可以通过IL-6/JAK2/STAT3途径调节PD-L1表达在骨髓瘤.
评估艾利对骨髓瘤中免疫逃避的作用.
评估艾利作为骨髓瘤免疫治疗的辅助剂的治疗潜力.

主要方法:

生物信息分析 (GEO,KEGG,GO) 确定了IL-6/JAK2/STAT3/PDL1通路.
在实验室研究中,使用HOS和K7M2骨髓瘤细胞系用艾利治疗.
在体内研究中,使用Balb/c小鼠模型治疗了艾利,分析了瘤微环境和免疫细胞透.

主要成果:

素治疗降低了IL-6/JAK2/STAT3通路的调节,并抑制了骨髓瘤细胞中的PD-L1表达.
阿利在体外抑制了骨髓瘤细胞的生长,迁移和入侵.
在体内,氨酸增加了CD4+和CD8+T细胞的透,增强了IFN-γ和大酶B的表达,并抑制了瘤免疫逃避.

结论:

氨酸通过调节IL-6/JAK2/STAT3通路来抑制PD-L1表达,从而增强抗瘤免疫反应.
阿利改善了瘤的微环境,并抑制了骨髓瘤中的免疫逃避.
阿利显示出作为骨髓瘤免疫疗法的辅助疗法具有显著的潜力.

关键词:

IL-6/JAK2/STAT3 是一个在PD-L1中.艾利素是一种素.免疫逃避免疫逃避骨质肉瘤是骨质肉瘤的一种疾病.

更多相关视频

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

相关概念视频

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...